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Abstract
Peripheral arterial disease (PAD) is a common, progressive manifestation of atherothrombotic
vascular disease, which should be managed no different to cardiac disease. Indeed, there is growing
evidence that PAD patients are a high risk group, although still relatively under-detected and under
treated. This is despite the fact that PAD patients are an increased mortality rate comparable to
those with pre-existing or established cardiovascular disease [myocardial infarction, stroke]. With
a holistic approach to atherothrombotic vascular disease, our management of PAD can only get
better.
Peripheral arterial disease (PAD) results from the narrow-
ing of the blood vessels of the lower limbs, predominantly
secondary to atherosclerotic vascular disease leading to
compromised blood flow to the lower limbs. Risk factors
associated with PAD include typical cardiovascular risk
factors, such as older age, cigarette smoking, diabetes mel-
litus, hypercholesterolemia, and hypertension [1]. PAD is
also very common in the western world – based on symp-
toms of intermittent claudication, PAD has a prevalence
of up to 5%, but a higher prevalence is estimated in the
general population [1,2]. As with much of cardiovascular
disease, PAD can be progressive, which about a third
report worsening symptoms and require surgical interven-
tions over 5 to 10 years [3] as well as suffer a higher cardi-
ovascular mortality risk [2-4]. One could argue that
compared to the large publicity and public health initia-
tives on heart attacks and strokes, public recognition on
the risks, morbidity and mortality associated with PAD
has been relatively neglected.
Given that the pathology in PAD arises secondary to
atherosclerosis (or atherothrombosis) affecting the vascu-
lar tree, PAD would be a very useful, subtle and early indi-
cator of a high risk population. The realisation that the
majority of those with PAD remain asymptomatic [4], and
that they can be more effectively identified by simple non-
invasive techniques warrants new hope for the primary
prevention of cardiovascular risk.
In their recent article published in BMC Cardiovascular
Disorders, Caro et al [5] embark upon estimating the bur-
den of cardiovascular risk in terms of mortality, morbidity
and associated risk factors in patients with PAD. Of note,
they compared outcomes between the PAD cohort to
those with reference populations with a first diagnosis of
myocardial infarction and stroke. They report that the
mortality rate amongst those with PAD was higher when
compared to those who had an index myocardial infarc-
tion but lower than those who had suffered stroke. Impor-
tantly, the rates were comparable to the other high risk
cohorts, with the crude five year death rate standing at
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33.2% [26.6% for index myocardial infarction; 41.8% for
index stroke]. Furthermore, at the end of the follow-up
period, half of the patients with PAD were alive, com-
pared to 59.6% of those in the myocardial infarction
group and 51.3% of those with stroke, respectively[5].
Broadly similar findings have also been reported in previ-
ous studies involving patients with PAD symptoms [6,7].
As expected, risk factor analyses revealed that men with
PAD were more likely to have atherothrombotic compli-
cations, angina, myocardial infarction, stroke, and death
[5]. Also, the risk of myocardial infarction was signifi-
cantly increased with in those aged over 65 years, espe-
cially with concomitant angina, diabetes mellitus, heart
failure, and hypertension – the increase in cardiovascular
risk in those with PAD was dependent on the number of
additional risk factors at the time of diagnosis in compar-
ison to those who did not have any other risk factors at
baseline, illustrating how risk factors are additive to each
other, resulting in a 'cumulative' cardiovascular risk[5].
The parallels with cardiac disease are uncanny.
The study by Caro et al [5] does merit some scrutiny. As it
is a database/registry-type study, and there are limitations
to the data presented. For instance, temporal changes in
blood pressures and laboratory values are not available
for further analyses, as well as detailed information on
optimization of medical therapies. Data on concomitant
risk factors such as atrial fibrillation [8] could have helped
in further understanding their long term impact on PAD
and outcome. Case ascertainment also remains an issue,
as the PAD cohort in the study by Caro et al [5] was iden-
tified based on the ICD codes used in case records.
Though different methods with varying complexities are
used currently [9], the ankle brachial pressure index seems
a simple effective and noninvasive solution and the best
mode for diagnosis. However, it would be a daunting task
to ensure confirmatory evidence in a standardized
detailed population examination of this magnitude. One
may argue that the patients with prior stroke and myocar-
dial infarction were at a better advantage, making them a
'more scrutinized' cohort with better provisions for active
secondary risk factor modification.
The conclusion that having PAD puts you at a much
higher risk which is comparable to the reference popula-
tions is therefore a justified one, and a message that needs
to be emphasized. Eventhough the majority of PAD sub-
jects remain asymptomatic, they remain a high-risk popu-
lation – probably even higher than those with single
cardiovascular risk factors. Of concern, risk factor reduc-
tion by lipid modifying therapy and antiplatelet therapy
in those with a diagnosis of PAD is less frequently applied
[10] in comparison to those with cardiac disease. Thus,
PAD patients may have had a less intensive risk reduction,
leading to a high cardiovascular event rate.
Should we be surprised? Cynical cardiologists would
argue that these aspects are well-known for heart disease,
but as PAD commonly presents to vascular surgeons (at
least in the UK) the onus is on them to initiate full cardi-
ovascular risk prevention therapies (a 'best medical ther-
apy' strategy), such as smoking cessation and the
aggressive treatment of hypertension and lipids. However,
many PAD patients also have cardiac problems, and may
attend blood pressure and lipid clinics. Perhaps the time
has come to organize vascular clinics jointly run by vascu-
lar surgeons and vascular physicians (even cardiologists!),
as one possible solution. The approach to the PAD patient
should not be simply surgery (or a stent) but should
include focus on aggressive risk factor modification
[11,12].
However, cardiac patients are blessed with many well con-
ducted large randomized controlled clinical trials, which
PAD patients often have to depend on subgroup analyses
from these studies to inform their management. Though
clinical trials of lipid-lowering therapy for patients with
PAD per se are not available, a systematic review by the
Cochrane collaboration of seven clinical trials [13] which
included 698 patients with PAD, showed a substantial but
not statistically significant reduction in total mortality
(odds ratio 0.21; 95% confidence interval [CI], 0.03–
1.17), with lipid-lowering therapy. Furthermore, there are
new studies indicating atherosclerosis regression with
aggressive lipid-lowering therapy and with antihyperten-
sive therapy, offering an effective interventional target
[14,15], again emphasising the role for aggressive risk fac-
tor modification. Antiplatelet therapy with aspirin or
thienopyridine drugs (ticlopidine and clopidogrel)
reduces the risk of cardiovascular events in patients with
established atherosclerosis [16], but in PAD patients
included in the Antithrombotic Trialists Collaboration
metaanalysis, there was no significant difference in cardi-
ovascular outcomes. As in cardiac disease, blockade of the
renin-angiotensin system may offer another therapeutic
target. For example, in the Heart Outcomes Prevention
Evaluation (HOPE) study [17], 44% of the study popula-
tion had PAD and an impressive reduction in cardiovascu-
lar events was seen in the ACE inhibitor (ramipril) group,
the reduction being independent of blood pressure reduc-
tion.
In conclusion, Caro et al [5] allows us to take stock of our
approach to managing PAD. PAD should be managed no
different to cardiac disease. Indeed, there is now growing
evidence that PAD patients are a high risk group, although
still relatively under-detected and under treated. This is
despite the fact that PAD patients are an increased mortal-Publish with BioMed Central    and   every 
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ity rate comparable to those with pre-existing or estab-
lished cardiovascular disease [myocardial infarction,
stroke]. With a holistic approach to atherothrombotic vas-
cular disease, our management of PAD can only get better.
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